News and Trends 14 Mar 2023Astellas menopause study meets endpoints but leukemia drug disappoints There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded… March 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 2 Mar 2023Could new dementia treatment come from intestinal bacteria discovery? Dementia with Lewy bodies (DLB), one of the most common forms of dementia, has no cure. Previous studies suggested that… March 2, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Mar 2023New lipid nanoparticle CRISPR delivery system developed Lipid nanoparticles have been used to encapsulate CRISPR-Cas9 and deliver it to cells in mice, where it was highly effective… March 2, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023Heartseed and Novo Nordisk dose first patient in heart failure cell therapy study Heartseed Inc. and Novo Nordisk A/S say Heartseed has successfully dosed the first patient in a phase 1/2 clinical study… February 10, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Feb 2023Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio This week, our guests are Romualda Stragienė, director at Innovation Agency Lithuania and Andrius Sliuzas, export key account manager of… February 10, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023New method to design new peptide therapeutics Researchers at Hokkaido University in Japan have developed a novel method to design and develop peptide antibiotics in large numbers,… February 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2023Lupus treatment hope from Japanese miRNA research A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of… January 26, 2023 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2023Ajinomoto and Exelixis to discover and develop novel ADCs to treat cancer Ajinomoto Co., Inc. has signed a license agreement with Exelixis, Inc. to incorporate AJICAP, Ajinomoto Co.'s proprietary site-specific bioconjugation and… January 12, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023Selecta and Astellas sign LOPD treatment agreement Selecta Biosciences, Inc. and Astellas Pharma Inc. have announced an exclusive licensing and development agreement for IdeXork (Xork). Xork is… January 9, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Dec 2022Japanese companies look to reduce environmental impact Japanese companies Astellas Pharma Inc., Eisai Co., Ltd., Daiichi Sankyo Company, Limited, and Takeda Pharmaceutical Company Limited have agreed a… December 22, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Dec 2022Artificial DNA can kill cancer Researchers at the University of Tokyo in Japan have used artificial DNA to target and kill cancer cells in a… December 21, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022Astellas gastric cancer drug meets phase 3 primary endpoint Astellas Pharma Inc. has announced positive topline results from the phase 3 GLOW clinical trial evaluating the efficacy and safety… December 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Dec 2022Sosei Heptares and Lilly enter agreement on diabetes and metabolic diseases Sosei Group Corporation has entered a drug discovery collaboration with Eli Lilly and Company to discover, develop and commercialize small… December 16, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 15 Dec 2022Cell reprogramming can reverse fibrosis after heart attack Researchers in Japan may have found a way to repair cardiac damage in patients suffering from chronic heart attack and… December 15, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Dec 2022Japanese research offers hope for Fukuyama muscular dystrophy patients Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of childhood muscular dystrophy in Japan. The disease manifests… December 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2022Scientists identify genetic variant causing ALS in some patients Researchers at Nagoya University in Japan have identified a novel genetic variant found in some patients with amyotrophic lateral sclerosis… December 7, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2022Arecor to start second type 2 diabetes clinical trial Arecor Therapeutics plc says the BASG (Bundesamt für Sicherheit im Gesundheitswesen) has cleared the company’s clinical trial application (CTA) for… November 22, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022Astellas meets primary endpoint in gastric cancer study Astellas Pharma Inc. has announced positive topline results from its phase 3 SPOTLIGHT clinical trial evaluating the efficacy and safety… November 17, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022New mitochondria study could pave way for disease treatments Mitochondria, the ‘powerhouses of the cell,’ are important cellular structures that are vital for their role of generating energy. They… November 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022Novel branched lipid boosts mRNA delivery to cells A novel branched lipid that is highly stable in storage and is highly efficient in delivering mRNA to cells has… November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email